Positioning Cenobamate in the Treatment Algorithm of Focal Epilepsy: Seizure Control and Benefits Beyond Seizures.

Authors

Manuel Toledo, Vicente Villanueva, Irene García-Morales, Juan Jesús Rodríguez-Uranga, Mar Carreño, José María Serratosa

Published in

Neurology and therapy. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

This work integrates the opinion on the current use of cenobamate (CNB) of an expert panel structured across seven thematic domains: efficacy, patient profiles, titration and dosing, pharmacokinetic interactions, safety, parallel effects, and therapeutic positioning. According to personal experience and scientific evidence, experts unanimously regarded CNB as likely more efficacious than other newer-generation antiseizure medications (ASMs), particularly based on the long-term sustained seizure-freedom rates, despite the absence of comparative head-to-head studies. Priority candidates are patients with focal epilepsy failing two or more ASMs, including older patients, with a clear inclination toward earlier introduction. Initial response is expected at 100-200 mg/day, although maintenance is typically 200 mg/day or higher, alongside reduction of concomitant ASMs particularly sodium channel blockers and benzodiazepines. The most relevant drug-drug interaction is with clobazam, which may have a synergistic efficacy effect and in parallel increases plasma concentrations of clobazam, thereby inducing adverse events. The most frequent adverse events (somnolence, dizziness, fatigue) are dose-dependent and are reduced by anticipatory reduction of concomitant medication. Beyond seizure reduction, an early intervention with CNB may modify the prognosis of epilepsy, reducing the long-term mortality risk, cognitive impairment, or psychiatric disorders. The panel converged on a priority to position CNB as a third-line treatment in the focal epilepsy treatment algorithm owing to its high efficacy, which will probably lead to modification of the long-term global outcomes of people with epilepsy.

PMID:
42888369
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.